3 completed, 2 terminated, 1 active not recruiting, 1 not yet recruiting. 4 Phase 2, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Not yet recruiting 1 |
| Not applicable | 1 | Terminated 1 |
Follow Moderate to Severe Ulcerative Colitis: new trials by email Literature Review of Moderate to Severe Ulcerative Colitis trials Research Report on Moderate to Severe Ulcerative Colitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of HRS-7085 Tablets in Patients With Moderate to Severe Active Ulcerative Colitis HRS-7085 tablets, Placebo - Moderate to Severe Ulcerative Colitis | Phase 1 | Not yet recruiting | Jiangsu HengRui Medicine Co., Ltd. | 8 | 2026-08-01 | 2026-08-12 |
| A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis Vixarelimab - Moderate to Severe Ulcerative Colitis | Phase 1 | Completed | Genentech, Inc. | 24 | 2025-03-31 | 2026-09-21 |
| Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis Hemay005 tablets, Hemay005 placebo tablets - Moderate to Severe Ulcerative Colitis | Phase 2 | Active not recruiting | Ganzhou Hemay Pharmaceutical Co., Ltd | 92 | 2022-11-08 | 2026-04-03 |
| Study on Variation of Serum and Fecal Biomarkers After Treatment to Predict Mucosal Healing in Patients With Ulcerative Colitis Serum and fecal measurements - Moderate to Severe Ulcerative Colitis | Not applicable | Terminated | University Hospital, Clermont-Ferrand | 62 | 2021-06-25 | 2026-06-17 |
| A Cohort Study Comparing IFX to CS for Moderate to Severe UC Infliximab, Corticosteroid - Moderate to Severe Ulcerative Colitis | Unknown | Sixth Affiliated Hospital, Sun Yat-sen University | 342 | 2021-05-17 | 2022-11-25 | |
| A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis Induction- PF-06480605 50 mg SC Q4W, Induction- PF-06480605 150 mg SC Q4W, Induction- PF-06480605 450 mg SC Q4W - Moderate to Severe Ulcerative Colitis | Phase 2 | Completed | Hoffmann-La Roche | 246 | 2019-12-19 | 2026-07-17 |
| A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC) Double-Blind 0.2mg CBP-307, Double-Blind Placebo, Open-label CBP-307 - Moderate to Severe Ulcerative Colitis | Phase 2 | Completed | Connect Biopharm LLC | 145 | 2019-02-27 | 2024-05-06 |
| A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis Itacitinib, Placebo - Moderate to Severe Ulcerative Colitis | Phase 2 | Withdrawn | Incyte Corporation | 2018-09-20 | 2019-12-06 | |
| Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo Moderate to Severe Ulcerative Colitis | Terminated | AbbVie | 10 | 2014-07-01 | 2017-02-23 |
Colitis, Ulcerative (3) · Inflammatory Bowel Diseases (1)
Colitis (3) · Colonic Diseases (3) · Digestive System Diseases (3) · Gastroenteritis (3) · Gastrointestinal Diseases (3) · Intestinal Diseases (3) · Inflammatory Bowel Diseases (2)
Adrenal Cortex Hormones (1) · Double-Blind Method (1) · Hemay005 (1) · INCB039110 (1) · Infliximab (1) · itacitinib (1)
AbbVie (1) · Connect Biopharm LLC (1) · Ganzhou Hemay Pharmaceutical Co., Ltd (1) · Genentech, Inc. (1) · Hoffmann-La Roche (1) · Incyte Corporation (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1) · University Hospital, Clermont-Ferrand (1)
China (3) · France (2) · Germany (2) · Ukraine (2) · United States (2) · Australia (1) · Belgium (1) · Bulgaria (1) · Colombia (1) · Hungary (1) · India (1) · Italy (1) · Japan (1) · Mexico (1) · Moldova (1)
Alexander Dorr, MD (1) · Kurt Brown, MD (1) · Shutian Zhang, MD (1) · Suzhou Connect (1)
2019 (1)